Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Motif A Step Closer To Succeeding With Iclaprim After Phase III Success

Executive Summary

Biotech firm hopes its once-shelved antibiotic will provide a therapeutic option for renally impaired patients with serious skin infections. With only one previous DHFR inhibitor ever approved, Motif also anticipates that iclaprim will offer an option for multidrug-resistant infections.


Related Content

Motif Bio Poised For Filings As Iclaprim Succeeds Again In Phase III
Antibiotic Pipeline Profile: Balancing Broad Spectrum And Limited Use
Motif Bio Seeks Cash For Novel Antibiotic
Keeping Track: FDA Clears Big Batch Of Products; 'Breakthrough' For Bristol HIV Drug
Pulling iclaprim out of the ashes
US panel knocks efficacy of Arpida's iclaprim for skin infections


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts